Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[212Pb]Pb-PSV359 in FAP-Positive Solid Tumors
NCT06710756Phase 2Recruiting
- Sponsor
- Perspective Therapeutics, Inc.
- Start
- Apr 2025
- Primary completion
- Jan 2028
- Modality
- Antibody-Radionuclide Conjugates, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 2, open-label trial of [212Pb]Pb-PSV359 in solid tumor (2 arms), sponsored by Perspective Therapeutics, Inc. Primary endpoints: Determination of safety and tolerability of [203Pb]Pb-PSV359 at 30 days, Determination of safety and tolerability of [212Pb]Pb-PSV359 at 3 years and 1 more. Started Apr 2025; status: recruiting.
02
Drugs
[212Pb]Pb-PSV359
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06710756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06710756.